# Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

> **NCT07428538** · PHASE3 · RECRUITING · sponsor: **Bausch Health Americas, Inc.** · enrollment: 350 (estimated)

## Conditions studied

- Hepatitis

## Interventions

- **DRUG:** Larsucosterol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07428538
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2027-11
- **Final completion:** 2028-02
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428538, "Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT07428538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*